Eli Lilly and Company

NYSE:LLY

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

💊 Drugstores & Retail Pharmacies

💊 Pharmaceuticals

Location

United States

Market Cap

USD 735.57 B

Share Price

USD 819.36

Avg Daily Volume

4,188,687

Change (1 day)

0.90%

Change (1 year)

-7.24%

Change (YTD)

6.13%

Eli Lilly and Company Price to Earnings Ratio (P/E) on June 13, 2025: 66.23

Eli Lilly and Company Price to Earnings Ratio (P/E) is 66.23 on June 13, 2025, a -48.81% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

Eli Lilly and Company 52-week low Price to Earnings Ratio (P/E) is 133.15 on June 13, 2025, which is 101.05% above the current Price to Earnings Ratio (P/E).
Eli Lilly and Company 52-week low Price to Earnings Ratio (P/E) is 57.69 on June 13, 2025, which is -12.89% below the current Price to Earnings Ratio (P/E).
Eli Lilly and Company average Price to Earnings Ratio (P/E) for the last 52 weeks is 86.87.

Daily

From:

To:

Zoom:

Key data

Date	Price to Earnings Ratio (P/E)	Price to Book Ratio (P/B)	Price to Sales Ratio (P/S)	Enterprise Value to EBITDA (EV/EBITDA)

NYSE: LLY

Eli Lilly and Company

CEO	Mr. David A. Ricks
IPO Date	June 1, 1972
Location	United States
Headquarters	Lilly Corporate Center
Employees	47,000
Sector	🏥 Health Care
Industries Clinical Trials 💊 Drugstores & Retail Pharmacies 💊 Pharmaceuticals

Description

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.